{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11"],"submitter":["Borghi L"],"pubmed_abstract":["Achievement of deep molecular response following treatment with a tyrosine kinase inhibitor (TKI) allows for treatment-free remission (TFR) in many patients with chronic myeloid leukemia (CML). Successful TFR is defined as the achievement of a sustained molecular response after cessation of ongoing TKI therapy. The phase 3 ENESTPath study was designed to determine the required optimal duration of consolidation treatment with the second-generation TKI, nilotinib 300 mg twice-daily, to remain in successful TFR without relapse after entering TFR for 12 months. The purpose of this Italian 'patient's voice CML' substudy was to evaluate patients' psycho-emotional characteristics and quality of life through their experiences of stopping treatment with nilotinib and entering TFR. The purpose of th"],"journal":["Frontiers in oncology"],"pagination":["638689"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8189147"],"repository":["biostudies-literature"],"pubmed_title":["Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy."],"pmcid":["PMC8189147"],"pubmed_authors":["Cuneo A","Di Caprio L","Bonifacio M","Crugnola M","Supekar S","Elena C","Vegni E","Borghi L","Cambrin GR","Sportoletti P","Iurlo A","Breccia M","Minotto C","Ciceri F","Maggi A","Capochiani E","Di Bona E","Sica S","Rosti G","Albano F","Capodanno I","Rivellini F","Arcaini L","Galimberti S","La Barba G","Baccarani M"],"additional_accession":[]},"is_claimable":false,"name":"Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy.","description":"Achievement of deep molecular response following treatment with a tyrosine kinase inhibitor (TKI) allows for treatment-free remission (TFR) in many patients with chronic myeloid leukemia (CML). Successful TFR is defined as the achievement of a sustained molecular response after cessation of ongoing TKI therapy. The phase 3 ENESTPath study was designed to determine the required optimal duration of consolidation treatment with the second-generation TKI, nilotinib 300 mg twice-daily, to remain in successful TFR without relapse after entering TFR for 12 months. The purpose of this Italian 'patient's voice CML' substudy was to evaluate patients' psycho-emotional characteristics and quality of life through their experiences of stopping treatment with nilotinib and entering TFR. The purpose of th","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-04-22T00:37:37.45Z","creation":"2022-02-10T14:56:19.097Z"},"accession":"S-EPMC8189147","cross_references":{"pubmed":["34123791"],"doi":["10.3389/fonc.2021.638689"]}}